Answer
If therapeutic alternatives are available, FEIBA is contraindicated in hypersensitivity to its active substance or any excipient, disseminated intravascular coagulation (DIC), or acute thrombosis or embolism, including myocardial infarction.
Sources for this answer
- FEIBA 100 U/ml powder and solvent for solution for infusionTakeda UK Ltd · emc · SmPC §4.3 Contraindications · Version 2Document updated
Sources checked